KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash & Equivalents (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Cash & Equivalents for 17 consecutive years, with $420.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 23.5% to $420.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $420.0 million through Dec 2025, down 23.5% year-over-year, with the annual reading at $420.0 million for FY2025, 23.5% down from the prior year.
  • Cash & Equivalents hit $420.0 million in Q4 2025 for Quest Diagnostics, down from $432.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.2 billion in Q1 2021 to a low of $126.0 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $535.6 million across 5 years, with a median of $511.5 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: plummeted 84.05% in 2023 and later soared 434.27% in 2024.
  • Year by year, Cash & Equivalents stood at $872.0 million in 2021, then plummeted by 63.88% to $315.0 million in 2022, then soared by 117.78% to $686.0 million in 2023, then dropped by 19.97% to $549.0 million in 2024, then fell by 23.5% to $420.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for DGX at $420.0 million in Q4 2025, $432.0 million in Q3 2025, and $319.0 million in Q2 2025.